Sooma Medical—the company behind the Sooma tDCS Therapy Kits—has just secured a US patent for its new tDCS electrode.
The electrode was developed to essentially be superior to other market tDCS electrodes in terms of decreased resistance at skin-electrode interface, decreased time for electrode preparation, and increased stimulation dosage accuracy. The electrode can also stay on the skin longer than other market tDCS electrodes while maintaining a stable connection quality.
This new electrode further reinforces the incremental trend we are seeing in tDCS toward safer and easier-to-use solutions in tDCS delivery.
![](https://images.squarespace-cdn.com/content/v1/5c007bfb2971147a30780a48/1617035507819-IUVRCUCVB10WPGRVTA2F/Caputron%2BtDCS%2BAd%2BBanner%2B728x90.jpeg?format=1500w)
Sooma products—along with the new tDCS electrode—are distributed in over 30 different countries. For those in the US, the Sooma system is sold under Caputron.
Sources: